Physician profile
Miae Oh
NPI 1740455013
$18,899.12
in general payments reported to CMS, 2019-2025
40 companies · $4,336 in 2025
The $4,336 reported for 2025 was more than what 82% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $391 · 2021: $1,395 · 2022: $2,942 · 2023: $3,330 · 2024: $6,211 · 2025: $4,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $2,532 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,017.91 |
| Consulting Fee | $2,531.75 |
| Education | $327.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $3,650.57 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $3,205.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,868.56 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $1,839.64 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Glaxosmithkline, LLC. | $1,296.55 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,235.90 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Amgen INC. | $742.43 | 2021-2025 | Tezspire |
| Optinose US, INC. | $614.51 | 2020-2025 | |
| Biocryst US Sales Co., LLC | $483.06 | 2021-2025 | Orladeyo |
| Pfizer INC. | $399.04 | 2019-2025 | |
| Pharming Healthcare, INC. | $355.31 | 2021-2025 | Ruconest, Joenja |
| Grifols USA, LLC | $274.55 | 2019-2025 | Xembify |
| Genentech USA, INC. | $190.34 | 2023-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $181.48 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $165.31 | 2021-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $156.90 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $156.88 | 2023-2024 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $140.33 | 2023-2025 | |
| Kaleo, INC. | $110.61 | 2019-2024 | Auvi-Q |
| Phathom Pharmaceuticals, INC. | $105.41 | 2024-2025 | Voquezna |
| Alk-Abello, INC | $91.76 | 2021-2023 | Ragwitek, Odactra, Grastek |
| Phadia US INC. | $71.64 | 2022-2025 | Immunocap |
| Organogenesis INC. | $60.49 | 2024-2025 | Affinity |
| Stryker Corporation | $56.12 | 2021 | |
| Paratek Pharmaceuticals, INC. | $53.37 | 2025 | Xhance |
| Covis Pharma Gmbh | $44.45 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.34 | 2020-2023 | Spiriva Respimat |
| Acclarent, INC | $38.26 | 2022 | |
| Inspire Medical Systems, INC. | $37.93 | 2023 | Inspire |
| Shire North American Group INC | $32.23 | 2019 | |
| Incyte Corporation | $27.82 | 2023 | Opzelura |
| Bio Products Laboratory USA, INC. | $27.72 | 2022-2023 | Gammaplex, Coagadex |
| Merck Sharp & Dohme LLC | $26.61 | 2021-2023 | |
| Intersect Ent, INC. | $26.59 | 2022 | |
| Cycle Pharmaceuticals INC | $25.16 | 2024 | Sajazir |
| Hikma Pharmaceuticals USA | $17.38 | 2023 | Mitigare, Ryaltris |
| Sunovion Pharmaceuticals INC. | $16.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.47 | 2020 | |
| Axogen | $13.33 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Ha+ Nerve Protector |
| Organon LLC | $2.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miae Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.